l-Thyroxine contamination of pharmaceutical d-thyroxine: probable cause of therapeutic effect

William Francis Young, Colum A. Gorman, Nai Siang Jiang, Dwaine Machacek, Ian D Hay

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Studies have shown that pharmaceutic preparations of the stereo isomers of thyroxine differ with respect to thyromimetic potency and lipid level-lowering effects. We applied a stereospecific assay for dextrothyroxine (DT4) and levothyroxine (LT4) to determine whether the biologic effects observed after the administration of (DT4) (Choloxin; Flint Laboratories) resulted from inherent biologic activity of DT4, conversion of (DT4) to LT4 in vivo, or LT4 contamination of Choloxin tablets. Choloxin was administered in a dose of 8 mg/day for 5 mo to nine athyreotic subjects who were then treated with pharmaceutic LT4 (Synthroid), 0.2 mg/day for an additional 5 mo. Analysis showed that LT4 contamination of Choloxin tablets ranged from 0.50% to 2.30%. This degree of contamination resulted in physiologically significant doses of LT4 in the 8 mg/day doses of Choloxin. During the treatment with two different lots of Choloxin, serum LT4 accounted for 33% to 53% of the measurable serum total thyroxine. The degree of LT4 contamination in Choloxin tablets was sufficient to account for the observed serum LT4 levels and casts doubt on the conclusions derived from previous studies in which Choloxin was used as the source of "(DT4)".

Original languageEnglish (US)
Pages (from-to)781-787
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume36
Issue number6
StatePublished - Dec 1984

Fingerprint

Dextrothyroxine
Therapeutic Uses
Thyroxine
Pharmaceutical Preparations
Tablets
Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

l-Thyroxine contamination of pharmaceutical d-thyroxine : probable cause of therapeutic effect. / Young, William Francis; Gorman, Colum A.; Jiang, Nai Siang; Machacek, Dwaine; Hay, Ian D.

In: Clinical Pharmacology and Therapeutics, Vol. 36, No. 6, 12.1984, p. 781-787.

Research output: Contribution to journalArticle

@article{da0b3b6b1e5d4afbb2e0b17aad824f1e,
title = "l-Thyroxine contamination of pharmaceutical d-thyroxine: probable cause of therapeutic effect",
abstract = "Studies have shown that pharmaceutic preparations of the stereo isomers of thyroxine differ with respect to thyromimetic potency and lipid level-lowering effects. We applied a stereospecific assay for dextrothyroxine (DT4) and levothyroxine (LT4) to determine whether the biologic effects observed after the administration of (DT4) (Choloxin; Flint Laboratories) resulted from inherent biologic activity of DT4, conversion of (DT4) to LT4 in vivo, or LT4 contamination of Choloxin tablets. Choloxin was administered in a dose of 8 mg/day for 5 mo to nine athyreotic subjects who were then treated with pharmaceutic LT4 (Synthroid), 0.2 mg/day for an additional 5 mo. Analysis showed that LT4 contamination of Choloxin tablets ranged from 0.50{\%} to 2.30{\%}. This degree of contamination resulted in physiologically significant doses of LT4 in the 8 mg/day doses of Choloxin. During the treatment with two different lots of Choloxin, serum LT4 accounted for 33{\%} to 53{\%} of the measurable serum total thyroxine. The degree of LT4 contamination in Choloxin tablets was sufficient to account for the observed serum LT4 levels and casts doubt on the conclusions derived from previous studies in which Choloxin was used as the source of {"}(DT4){"}.",
author = "Young, {William Francis} and Gorman, {Colum A.} and Jiang, {Nai Siang} and Dwaine Machacek and Hay, {Ian D}",
year = "1984",
month = "12",
language = "English (US)",
volume = "36",
pages = "781--787",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - l-Thyroxine contamination of pharmaceutical d-thyroxine

T2 - probable cause of therapeutic effect

AU - Young, William Francis

AU - Gorman, Colum A.

AU - Jiang, Nai Siang

AU - Machacek, Dwaine

AU - Hay, Ian D

PY - 1984/12

Y1 - 1984/12

N2 - Studies have shown that pharmaceutic preparations of the stereo isomers of thyroxine differ with respect to thyromimetic potency and lipid level-lowering effects. We applied a stereospecific assay for dextrothyroxine (DT4) and levothyroxine (LT4) to determine whether the biologic effects observed after the administration of (DT4) (Choloxin; Flint Laboratories) resulted from inherent biologic activity of DT4, conversion of (DT4) to LT4 in vivo, or LT4 contamination of Choloxin tablets. Choloxin was administered in a dose of 8 mg/day for 5 mo to nine athyreotic subjects who were then treated with pharmaceutic LT4 (Synthroid), 0.2 mg/day for an additional 5 mo. Analysis showed that LT4 contamination of Choloxin tablets ranged from 0.50% to 2.30%. This degree of contamination resulted in physiologically significant doses of LT4 in the 8 mg/day doses of Choloxin. During the treatment with two different lots of Choloxin, serum LT4 accounted for 33% to 53% of the measurable serum total thyroxine. The degree of LT4 contamination in Choloxin tablets was sufficient to account for the observed serum LT4 levels and casts doubt on the conclusions derived from previous studies in which Choloxin was used as the source of "(DT4)".

AB - Studies have shown that pharmaceutic preparations of the stereo isomers of thyroxine differ with respect to thyromimetic potency and lipid level-lowering effects. We applied a stereospecific assay for dextrothyroxine (DT4) and levothyroxine (LT4) to determine whether the biologic effects observed after the administration of (DT4) (Choloxin; Flint Laboratories) resulted from inherent biologic activity of DT4, conversion of (DT4) to LT4 in vivo, or LT4 contamination of Choloxin tablets. Choloxin was administered in a dose of 8 mg/day for 5 mo to nine athyreotic subjects who were then treated with pharmaceutic LT4 (Synthroid), 0.2 mg/day for an additional 5 mo. Analysis showed that LT4 contamination of Choloxin tablets ranged from 0.50% to 2.30%. This degree of contamination resulted in physiologically significant doses of LT4 in the 8 mg/day doses of Choloxin. During the treatment with two different lots of Choloxin, serum LT4 accounted for 33% to 53% of the measurable serum total thyroxine. The degree of LT4 contamination in Choloxin tablets was sufficient to account for the observed serum LT4 levels and casts doubt on the conclusions derived from previous studies in which Choloxin was used as the source of "(DT4)".

UR - http://www.scopus.com/inward/record.url?scp=0021719132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021719132&partnerID=8YFLogxK

M3 - Article

C2 - 6499357

AN - SCOPUS:0021719132

VL - 36

SP - 781

EP - 787

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -